In a move to broadly unlock Dynamic Single-Molecule (DSM) analysis, LUMICKS simultaneously launched two major initiatives: a new business line for reagents, biochemistry kits, and services, as well as its Harbor platform for sharing of DSM scripts. These new resources dramatically simplify the experimental workflow and make DSM analysis accessible across different fields and expertise levels.
The Reagents, Kits, and Services Store offers an extensive selection of pre-developed and qualified consumables, samples, protocols, and tailored services for custom biochemistry and experimental design. The portfolio includes a variety of products for DNA, RNA, and protein folding assays, eliminating the need for users to invest money, time, and personnel in setting up experimental workflows.
The script-sharing platform Harbor is a free, open-access portal where users can publish, download, review, and cite scripts that automate DSM experiments and analyze extracted data. Elements, such as the build-in citation section and interaction indicators (likes, downloads, comments), are used by both novice and expert users to review scripts, cite them, and highlight golden standard methods. These scripts run directly within the control software of LUMICKS instruments.
“This is a major step forward in broadly unlocking Dynamic Single-Molecule analysis to the broader biology community,” said Olivier Heyning, CEO at LUMICKS. “With our reagents and kits, users can get started with meaningful experiments in a matter of days. With the Harbor platform, we took the strategic choice to closely collaborate with our user community to break the barriers by establishing and continuously improving the informatics toolbox for single-molecule experiments and analysis. This makes DSM research accessible to all types of users, regardless of experience level and scientific focus area.”
LUMICKS (spin-off Vrije Universiteit Amsterdam) is a leading life sciences company that develops equipment for dynamic single-molecule and cell avidity analysis, two emerging areas in biology research and immuno-oncology (IO). Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018), STED super-resolution (Nobel Prize for Chemistry 2014), and acoustic force spectroscopy, LUMICKS tools facilitate the understanding of life to the smallest detail. Applying and measuring forces in biology enables real-time analysis of true biological mechanisms. This creates the crucial and yet unexplored bridge between structure and function at the molecular and cellular level. The latest technology in the company’s arsenal, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells. This technology is game-changing for the development and application of IO therapies for the treatment of cancer.
The Dutch government’s yearly national budget, the Miljoenennota, initiates a budget implementation cycle. This consists of various phases; spending, adjusting, auditing and reporting. During this cycle, the Dutch Ministry of Finance collects a multitude of reports and other information resources, originating from various government sources. The Ministry used to manually copy the data and use […]News
Amsterdam Venture Studio’s startup Findest scouts technologies by using IGOR^AI. A Finnish electricity grid operator Fingrid Oyj used IGOR^AI to find out how they could increase the transmission capacity or eliminate bottlenecks. In Fingrid magazine the company shared their experience, arguing that “[IGOR^AI] is one of the first applications to really demonstrate how artificial intelligence […]News
Johan Hoorn en Elly Konijn hebben voor hun onderzoeksproject ‘Alice’ de Huibregtsenprijs ontvangen. ‘Alice’ is een elektromechanisch kleinkind dat eenzaamheid verdrijft. In een vegrijzende samenleving is sociale eenzaamheid een groot problem. Om die reden ontwikkelden de onderzoekers ‘Alice’. Het robotmeisje vereist een vorm van interactie waarbij het AI-systeem gevoel voor de gebruiker ten toon kan spreiden en de […]News